An Open-label, Multi-Centre Trial Investigating Pharmacokinetics of Degarelix After a Starting Dose of 240 mg (40 mg/mL) Followed by Six Maintenance Doses of 80 mg (20 mg/mL) in Chinese Patients With Prostate Cancer Requiring Androgen Deprivation Therapy

Trial Profile

An Open-label, Multi-Centre Trial Investigating Pharmacokinetics of Degarelix After a Starting Dose of 240 mg (40 mg/mL) Followed by Six Maintenance Doses of 80 mg (20 mg/mL) in Chinese Patients With Prostate Cancer Requiring Androgen Deprivation Therapy

Completed
Phase of Trial: Phase I

Latest Information Update: 31 Oct 2017

At a glance

  • Drugs Degarelix (Primary)
  • Indications Prostate cancer
  • Focus Pharmacokinetics
  • Sponsors Ferring Pharmaceuticals
  • Most Recent Events

    • 25 Oct 2017 Status changed from active, no longer recruiting to completed.
    • 18 Apr 2016 Planned End Date changed from 1 Jul 2016 to 1 Oct 2017.
    • 18 Apr 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Oct 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top